Sangamo BioSciences to Develop Cell-based Assays for Pharmacia | GenomeWeb

NEW YORK, July 17 – Sangamo BioSciences has agreed to prepare genetically engineered cells and deliver them to Pharmacia for screening small molecule drugs, Sangamo said Tuesday.

Sangamo, of Richmond, Calif., will use its zinc finger DNA-binding protein transcription factor (ZFP TF) technology to overexpress certain proteins in cell lines. Pharmacia, based in Peapack, NJ, will take the cells and use them to screen its library of small molecule compounds to determine how well they bind with the proteins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.